Elan Corp, plc (ADR) (NYSE:ELN.DL)

CAPS Rating: No stars

The Company's Biopharmaceuticals unit is engaged in research, development and commercial activities and its EDT unit focuses on product development, scale-up and manufacturing to address drug optimization challenges of the pharmaceutical industry.

Recs

5
Player Avatar michjksn (< 20) Submitted: 2/27/2009 1:42:57 PM : Underperform Start Price: $6.26 ELN.DL Score: -47.42

Historically poorly run company. One product which causes death all too often/terrible press. No products on horizon, including Bap, worth anything other than being money pits for underachievement. What R&D there was, has been all but killed off due to debt load, which is overwhelming and coming due in the near future. Convoluted ownership of company parts precludes any sale.

Featured Broker Partners


Advertisement